EGFR Mutations Detection in Non-small Cell Lung Cancer Tissues by Real-time PCR and DNA Sequencing

• Main Authors: Qinghua ZHOU, Jun CHEN, Jing WANG, Yuli WANG, Ying LI, Hongyu LIU, Yongwen LI
• Format: Article
• Language: zho
• Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2009-12-01
• Series: Chinese Journal of Lung Cancer
• Subjects: Epidermal growth factor receptor (EGFR); Mutations; Real-time PCR; DNA sequencing
• Online Access: http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.06&path[]=1230

Background and objective Small molecule tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib that target the kinase domain of epidermal growth factor receptor (EGFR) are making successful progression for advanced non-small cell lung cancer patients treatment. The growing evidences revealed that EGFR exon 19 and 21 mutation status in NSCLC patients was correlated with the outcome for EGFR-TKI treatment. In this study, two methods of Real-time PCR and DNA sequencing were compared to detected EGFR exon 19 and 21 mutations. Methods EGFR exon19 mutation del-E746-A750 and exon 21mutation L858R were detected by Real-time PCR and DNA sequencing in 103 NSCLC patients. Chi-square test was used to analyze the consistance. Results There was no significant difference between the two methods. However, Real-time PCR was more convenient and sensitive compared to DNA sequencing. Conclusion Real-time PCR was more suitable for clinical testing than DNA sequencing.